Journal: Oncology Letters

Article Title: Bone mesenchymal stem cell‑derived exosome‑encapsulated microRNA‑125b‑5p inhibits ovarian cancer progression via DDX5 downregulation

doi: 10.3892/ol.2025.15001

Figure Lengend Snippet: Identification of BMSCs and exosomes. (A) Stem cell markers detected using flow cytometry. (B) Oil Red O and Alizarin Red staining of BMSCs. Scale bar, 100 µm. (C) Representative transmission electron microscopy images of exosomes. Scale bar, 100 nm. (D) Nanoparticle tracking analysis detected the diameter and concentration of exosomes. (E) Western blot analysis of the exosomal markers, CD9 and CD81, with GAPDH as a loading controls. (F) The gene expression levels of miR-125b-5p in BMSCs transfected with miR-125b-5p mimic. (G) PKH26-labeled exosomes in SKOV3 cells. Scale bar, 25 µm. (H) miR-125b-5p gene expression levels in Exo-miR-125b-5p mimic and Exo-mimic were assessed. Data were represented by the mean ± standard deviation. *P<0.05. BMSCs, bone mesenchymal stem cells; miR-125b-5p, microRNA-125b-5p; NC, negative control; Exo-, exosome encapsulated.

Article Snippet: The aforementioned vectors and plasmids used for transfection were purchased from Shanghai GenePharma Co., Ltd., and the miR-125b-5p mimic (cat. no. MC10148) and mimic NC (cat. no. 4464059) were purchased from Thermo Fisher Scientific, Inc. ( ).

Techniques: Flow Cytometry, Staining, Transmission Assay, Electron Microscopy, Concentration Assay, Western Blot, Gene Expression, Transfection, Labeling, Standard Deviation, Negative Control

Journal: Oncology Letters

Article Title: Bone mesenchymal stem cell‑derived exosome‑encapsulated microRNA‑125b‑5p inhibits ovarian cancer progression via DDX5 downregulation

doi: 10.3892/ol.2025.15001

Figure Lengend Snippet: BMSCs-Exo limits malignancy of OC cells. (A) miR-125b-5p gene expression levels evaluated in SKOV3 cells treated with BMSCs-Exo. (B) Proliferation of OC cells examined using the CCK-8 assay after BMSCs-Exo treatment. (C) Migration of OC cells assessed using a scratch test after BMSCs-Exo treatment (scale bar, 200 µm; magnification, ×100). (D) Invasion of OC cells evaluated using a Transwell assay after BMSCs-Exo treatment (scale bar, 50 µm; magnification, ×200). (E) Apoptosis of OC cells examined using flow cytometry after BMSCs-Exo treatment. Data were represented by the mean ± standard deviation. *P<0.05. BMSCs-Exo, bone mesenchymal stem cells-derived exosomes; OC, ovarian cancer; OD, optical density.

Article Snippet: The aforementioned vectors and plasmids used for transfection were purchased from Shanghai GenePharma Co., Ltd., and the miR-125b-5p mimic (cat. no. MC10148) and mimic NC (cat. no. 4464059) were purchased from Thermo Fisher Scientific, Inc. ( ).

Techniques: Gene Expression, CCK-8 Assay, Migration, Transwell Assay, Flow Cytometry, Standard Deviation, Derivative Assay

Journal: Oncology Letters

Article Title: Bone mesenchymal stem cell‑derived exosome‑encapsulated microRNA‑125b‑5p inhibits ovarian cancer progression via DDX5 downregulation

doi: 10.3892/ol.2025.15001

Figure Lengend Snippet: Exosome delivery of miR-125b-5p represses malignant progression of OC cells. (A) Gene expression levels of miR-125b-5p in normal ovarian tissues and OC tissues detected. (B) miR-125b-5p gene expression levels in SKOV3 cells treated with Exo-miR-125b-5p mimic and Exo-mimic NC. (C) Proliferation of OC cells examined using the CCK-8 assay after Exo-miR-125b-5p mimic treatment. (D) Migration of OC cells evaluated using a scratch test after Exo-miR-125b-5p mimic treatment (scale bar, 200 µm; magnification, ×100). (E) Invasion of OC cells assessed using a Transwell assay after Exo-miR-125b-5p mimic treatment (scale bar, 50 µm; magnification, ×200). (F) Apoptosis of OC cells examined using flow cytometry after Exo-miR-125b-5p mimic treatment. Data were represented by the mean ± standard deviation. *P<0.05. OC, ovarian cancer; OD, optical density; miR-125b-5p, microRNA-125b-5p; NC, negative control; Exo-, exosome encapsulated.

Article Snippet: The aforementioned vectors and plasmids used for transfection were purchased from Shanghai GenePharma Co., Ltd., and the miR-125b-5p mimic (cat. no. MC10148) and mimic NC (cat. no. 4464059) were purchased from Thermo Fisher Scientific, Inc. ( ).

Techniques: Gene Expression, CCK-8 Assay, Migration, Transwell Assay, Flow Cytometry, Standard Deviation, Negative Control

Journal: Oncology Letters

Article Title: Bone mesenchymal stem cell‑derived exosome‑encapsulated microRNA‑125b‑5p inhibits ovarian cancer progression via DDX5 downregulation

doi: 10.3892/ol.2025.15001

Figure Lengend Snippet: Targeting relationship between miR-125b-5p and DDX5. (A) DDX5 mRNA and protein expression in normal ovarian and tumor tissues. (B) Targeted sites between miR-125b-5p and DDX5 using the ENCORI software. (C) Correlation between miR-125b-5p and DDX5 mRNA expression levels. The binding of miR-125b-5p and DDX5 was analyzed using (D) dual luciferase reporter and (E) RNA immunoprecipitation assays. (F) DDX5 mRNA and protein expression levels were evaluated in mimic NC and miR-125b-5p mimic group. (G) DDX5 mRNA expression levels were evaluated. Data were represented by the mean ± standard deviation. *P<0.05. OC, ovarian cancer; OD, optical density; miR-125b-5p, microRNA-125b-5p; NC, negative control; Exo-, exosome encapsulated; WT, wild-type; Mut, mutant; DDX, DEAD-box helicase 5.

Article Snippet: The aforementioned vectors and plasmids used for transfection were purchased from Shanghai GenePharma Co., Ltd., and the miR-125b-5p mimic (cat. no. MC10148) and mimic NC (cat. no. 4464059) were purchased from Thermo Fisher Scientific, Inc. ( ).

Techniques: Expressing, Software, Binding Assay, Luciferase, RNA Immunoprecipitation, Standard Deviation, Negative Control, Mutagenesis

Journal: Oncology Letters

Article Title: Bone mesenchymal stem cell‑derived exosome‑encapsulated microRNA‑125b‑5p inhibits ovarian cancer progression via DDX5 downregulation

doi: 10.3892/ol.2025.15001

Figure Lengend Snippet: DDX5 overexpression inhibits miR-125b-5p-induced suppression of OC development. (A) DDX5 mRNA expression in the pcDNA-NC group and pcDNA-DDX5 group. DDX5 (B) mRNA and (C) protein expression levels in the Exo-miR-125b-5p mimic + pcDNA-NC and Exo-miR-125b-5p mimic + pcDNA-DDX5 groups. (D) Proliferation of OC cells examined using the CCK-8 assay in the Exo-miR-125b-5p mimic + pcDNA-NC and Exo-miR-125b-5p mimic + pcDNA-DDX5 groups. (E) Migration of OC cells evaluated using a scratch test in the Exo-miR-125b-5p mimic + pcDNA-NC and Exo-miR-125b-5p mimic + pcDNA-DDX5 groups (scale bar, 200 µm; magnification, ×100). (F) Invasion of OC cells assessed using a Transwell assay in the Exo-miR-125b-5p mimic + pcDNA-NC and Exo-miR-125b-5p mimic + pcDNA-DDX5 groups (scale bar, 50 µm; magnification, ×200). (G) Apoptosis of OC cells examined using flow cytometry in the Exo-miR-125b-5p mimic + pcDNA-NC and Exo-miR-125b-5p mimic + pcDNA-DDX5 groups. Data were represented by the mean ± standard deviation. *P<0.05. OC, ovarian cancer; OD, optical density; miR-125b-5p, microRNA-125b-5p; NC, negative control; Exo-, exosome encapsulated; WT, wild-type; Mut, mutant; DDX, DEAD-box helicase 5; transfected using the pcDNA3.1 plasmid.

Article Snippet: The aforementioned vectors and plasmids used for transfection were purchased from Shanghai GenePharma Co., Ltd., and the miR-125b-5p mimic (cat. no. MC10148) and mimic NC (cat. no. 4464059) were purchased from Thermo Fisher Scientific, Inc. ( ).

Techniques: Over Expression, Expressing, CCK-8 Assay, Migration, Transwell Assay, Flow Cytometry, Standard Deviation, Negative Control, Mutagenesis, Transfection, Plasmid Preparation